<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685057</url>
  </required_header>
  <id_info>
    <org_study_id>PIC-194-20</org_study_id>
    <nct_id>NCT04685057</nct_id>
  </id_info>
  <brief_title>Probiotic Treatment for Prader-Willi Syndrome</brief_title>
  <official_title>Probiotics as a Long-term Treatment Strategy for Prader-Willi Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Sant Joan de Déu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Sant Joan de Déu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A whole new research area studying the function of intestinal microorganisms, also known as&#xD;
      gut microbiota, has emerged during the last decade. As a result, dietary supplementation with&#xD;
      specific bacteria (or probiotics) holds great promise as a therapeutic strategy for a wide&#xD;
      range of diseases, from obesity to anxiety and depression, all of which are major&#xD;
      characteristics of Prader-Willi syndrome (PWS).&#xD;
&#xD;
      The main objective of the current proposal is to determine the effects of Bifidobacterium&#xD;
      animalis subsp. lactis (strain BPL1) supplementation in children and young adults with PWS.&#xD;
      Specifically, participants will receive placebo or BPL1 for 6 months, and then this phase&#xD;
      will be followed by a 6-month extension period in which all participants will receive BPL1.&#xD;
      This study will allow us to 1) determine the effects on fat mass and glucose metabolism; and&#xD;
      2) explore the effects on mental health symptoms by studying potential structural changes in&#xD;
      the brain by magnetic resonance imaging (MRI) as well as using a number of psychiatric&#xD;
      questionnaires.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in percent body fat content</measure>
    <time_frame>6 months</time_frame>
    <description>Body fat content will be measured by dual energy x-ray absorptiometry (DXA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BMI and BMI z-score</measure>
    <time_frame>Baseline, 6, and 12 months</time_frame>
    <description>Weight and height will be combined to calculate changes in BMI and BMI z scores from all subjects will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in height (cm)</measure>
    <time_frame>Baseline, 6, and 12 months</time_frame>
    <description>Changes in height from subjects that have not yet reached final height will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin sensitivity</measure>
    <time_frame>Baseline, 6, and 12 months</time_frame>
    <description>Fasting blood glucose and insulin concentrations will be combined to calculate HOMA-IR (Homeostatic Model Assessment for Insulin Resistance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipid profile (triglyceride, cholesterol)</measure>
    <time_frame>Baseline, 6, and 12 months</time_frame>
    <description>Blood test after overnight fasting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hyperphagia</measure>
    <time_frame>Baseline, 6, and 12 months</time_frame>
    <description>Measured by the validated Hyperphagia Questionnaire for Clinical Trials (HQ-CT), specific for subjects with Prader-Willi syndrome (scale 0-36, higher values indicate higher degree of hiperphagia). Parental or caregiver reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aberrant Behavior Checklist (ABC) score</measure>
    <time_frame>Baseline, 6, and 12 months</time_frame>
    <description>The Aberrant Behavior Checklist (ABC) is a 58-item questionnaire. It consists of five subscales: hyperactivity (0-48), lethargy (0-48), stereotypical behavior (0-21), irritability (0-45), and inappropriate speech (0-12). Higher scores indicate worse outcome. Parental or caregiver reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Repetitive Behavior Scale (RBS) score</measure>
    <time_frame>Baseline, 6, and 12 months</time_frame>
    <description>The Repetitive Behavior Scale (RBS) measures repetitive behaviors that are related to autism. It consists of 43-items grouped in two different scores: higher-order (ritualistic, sameness, compulsive and restricted subscales; score 0-87) and lower-order (stereotypy and self-injury; score 0-42) repetitive behaviors. Higher scores indicate worse outcome. Parental or caregiver reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Social Responsiveness Scale (SRS) score</measure>
    <time_frame>Baseline, 6, and 12 months</time_frame>
    <description>Measured by the validated Social Responsiveness Scale (SRS-2) which assesses autism-related symptoms focusing on social function. Higher values indicate worse outcome. A total score of 76 or higher is considered severe; a score between 66 and 75 is considered moderate; a score between 60 and 65 is considered mild; a score of 59 or lower is considered within normal limits. Parental or caregiver reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression (GCI score) score</measure>
    <time_frame>Baseline, 6, and 12 months</time_frame>
    <description>Measured by the validated Clinical Global Impression Scale (CGI, scale 0-14, higher values indicate worse outcome). This toll will be completed by the clinician.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in intestinal microbiota composition</measure>
    <time_frame>Baseline, 6, and 12 months</time_frame>
    <description>DNA isolated from fecal samples will be analyzed by sequencing the hypervariable region of the bacterial 16S gene.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in plasma metabolome</measure>
    <time_frame>Baseline, 6, and 12 months</time_frame>
    <description>Liquid chromatography coupled to mass spectrometry will be used to obtain a comprehensive metabolic profile of plasma samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in brain structural anatomy</measure>
    <time_frame>Baseline, 6, and 12 months</time_frame>
    <description>Subjects older that 12 years of age will undergo brain magnetic resonance imaging (MRI). Changes in orbitofrontal cortex, amygdala, hypothalamus, and total gray matter volume will be evaluated.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will receive placebo for 6 months then probiotic for 6 more months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive probiotic for 6 months then will keep receiving probiotic for 6 more months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intervention with a daily dose of placebo for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Intervention with a daily dose of probiotic for 6 months</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Follow-up probiotic</intervention_name>
    <description>Intervention with a daily dose of probiotic for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with Prader-Willi Syndrome with genetic confirmation&#xD;
&#xD;
          -  On a stable diet and medication regimen for at least the last two months before&#xD;
             enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current enrollment in or discontinuation within the last 30 days from a clinical trial&#xD;
&#xD;
          -  Patients with bariatric surgery in the last two years&#xD;
&#xD;
          -  Patients with Type 2 Diabetes on insulin therapy&#xD;
&#xD;
          -  Presence of other medical problems that would preclude study participation&#xD;
&#xD;
          -  Unsuitable for inclusion in the study in the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Ramon-Krauel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sant Joan de Deu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carles Lerin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundació Sant Joan de Déu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

